Forest Labs buys Furiex for bowel drug


Forest Laboratories has agreed to buy Furiex pharmaceuticals for $1.1 billion (£650 million) in cash, with a top-up of up to $360 million contingent on approval of Furiex’s irritable bowel syndrome drug eluxadoline.

The drug will mesh quite well with Forest’s other gastrointestinal drug lines, many of which came from its acquisition of Aptalis at the beginning of the year. True to the company’s focus on innovative drugs, Forest has also said that, as soon as the deal goes through, it will sell Furiex’s royalty rights to diabetes drug alogliptin and premature ejaculation remedy Priligy (dapoxetine) to investment firm Royalty Pharma.

There is an interesting twist to the approval contingency payment, too. Because eluxadoline is an opioid receptor agonist, there is a possibility that it will be classified as a controlled substance by the US Drug Enforcement Agency (DEA). If this happens, the value of the top-up payment will go down depending on the level of restriction the DEA imposes.


Related Content

Megamerger brings Actavis into R&D race

25 February 2014 Business

news image

$25bn Forest Labs takeover will see generics giant take on patented products

Business roundup

29 March 2011 Business

news image

Industry news, April 2011

Most Read

Antimicrobial resistance will kill 300 million by 2050 without action

16 December 2014 News and Analysis

news image

UK report says resistance will cost global economy $100 trillion

Cutting edge chemistry in 2014

10 December 2014 Research

news image

We take a look back at the year's most interesting chemical science stories

Most Commented

Smart skin for prosthetic limbs senses heat and touch

12 December 2014 Research

news image

Ultra-thin plastic skin can bend and flex without affecting the skin's ability to detect stimuli

Chemistry behind the ‘blue man’ unlocked

1 November 2012 Research

news image

Biochemical model suggests that silver ions, not nanoparticles, cause a rare skin complaint